OSSIX® VOLUMAX - a New Ossifying Collagen Scaffold for GBR and GTR with Volume Maintaining Features - is now Health Canada Licensed
- OSSIX® VOLUMAX is commercially available in the USA, Europe, Korea, Israel and now Canada.
- Data presented at the AAP and EAO in September 2016, shows that OSSIX® VOLUMAX has the potential to augment thin tissue around implants, esthetic deficiencies and correct residual dehiscence after regenerative procedures.
- OSSIX® VOLUMAX is based on the same proven GLYMATRIX® technology as OSSIX® PLUS, the resorbable collagen membrane with more than a decade of use and over 100 clinical publications.
OTTAWA, Ontario, Jan. 26, 2017 /CNW/ -- Hesira Med announced that OSSIX® VOLUMAX has received Health Canada license, enabling the company to commercially market this new volumizing, thick (1-2mm) collagen scaffold within Canada. It is the newest addition to the OSSIX® line of dental regeneration products, developed and manufactured by Datum Dental, for use in periodontics, oral surgery, dental implantology and dental aesthetic procedures.
Data presented at the American Association of Periodontology (AAP) 102nd Annual Meeting Poster Session and at the European Association for Osseointegration (EAO) Congress in September 2016, clearly demonstrate statistically significant improved bone growth using OSSIX® VOLUMAX versus empty controls. The results also show OSSIX® VOLUMAX's mineralisation and ossification progress.
Dr. Yuval Zubery, DMD, Specialist in Periodontics and Chief Medical Officer at Datum Dental, believes that OSSIX® VOLUMAX has significant potential to restore lost volume in guided bone regeneration (GBR) and guided tissue regeneration (GTR) cases. "In implant surgery procedures where there is missing buccal bone, residual dehiscence or buccal dehiscence (video demonstration), this new thick collagen matrix restores lost volume. We are receiving excellent feedback from clinicians in countries where the product has already been approved. Some are also choosing OSSIX® VOLUMAX for use in the esthetic zone, especially for masking implants."
Mr. Itay Itzhaky, Chairman, Datum Dental said: "OSSIX® VOLUMAX and the well-known and decade-long proven OSSIX® PLUS both feature the sugar collagen cross linking GLYMATRIX® technology. This proprietary technology enables production of collagen matrices, which can be bio-programmed and tailored to deliver a range of products of varying physical properties, customized longevity and controlled rates of degradation. Over 100 publications have been published to date. We continue to develop products featuring this unique technology, for the benefit of patients and healthcare around the globe."
Mr. Chris Carriere, Managing Director, Hesira Med added: "We believe that Canadian clinicians deserve best-in-class dental regenerative materials in order to achieve ideal treatment outcomes for patients. We are proud to be bringing new and innovative products to Canada. OSSIX® PLUS and OSSIX™ GRAFT particulate allograft have been well received by clinicians. We are excited to be adding OSSIX® VOLUMAX to our product line, which was recently announced winner of the 2017 DrBicuspid.com Dental Excellence Award for Best New Restorative Material."
OSSIX® VOLUMAX is available in 4 sizes: 10 x 12.5, 15 x 25, 10 x 40, 25 x 30 mm.
Orders for OSSIX® VOLUMAX, OSSIX® PLUS and OSSIX™ GRAFT can be placed at HesiraMed.com, by email: [email protected] or call: 1-844-HESIRA-1.
For information on indications, contraindications, warnings and precautions please refer to instructions for use.
Hesira Med Inc. is a Canadian owned and operated medical device import and distribution company. We are passionate about delivering and marketing innovative, first-rate products to the Canadian dental industry. We strive to provide superior customer service and education in order to empower clinicians. The ultimate goal is improved health and quality of life for patients.
Contact:
[email protected]
1-844-HESIRA-1
HesiraMed.com
Twitter: @Hesira_Med
Facebook: HesiraMed
LinkedIn: Hesira-Med-Inc
SOURCE Datum Dental and Hesira Med
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2017/26/c6051.html
Share this article